$67.48
▲ +$0.69
(+1.03%)
Vol 1.3M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.3B
ROE
-21.7%
Margin
-5062.5%
D/E
0.44
Beta
1.97
52W
$15–$46
Wall Street Consensus
21 analysts · Apr 20265
Strong Buy
15
Buy
1
Hold
0
Sell
0
Strong Sell
95.2%
Buy Rating
Price Chart
Similar Stocks
ACLX
Arcellx Inc
$3.8B
PTGX
Protagonist Therapeutics Inc
P/E 118.9
$5.5B
RYTM
Rhythm Pharmaceuticals Inc
$7.1B
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8.1
$6.1B
ERAS
Erasca Inc
$1.1B
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
About CG Oncology, Inc. - Common stock
CGON - біотехнологічна компанія, що спеціалізується на розробці та комерціалізації інноваційних рішень для діагностики та лікування онкологічних захворювань. Компанія займає нішеву позицію на ринку, зосереджуючись на персоналізованій медицині та ранній діагностиці раку. Її ключова конкурентна перевага - запатентовані технології та партнерства з провідними дослідницькими установами.
Earnings
Beat rate: 50.0%
Next Report
May 11, 2026
EPS Estimate: $-0.59
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.59 | — | — |
| Dec 2025 | $-0.63 | $-0.53 | +$0.10 |
| Sep 2025 | $-0.57 | $-0.57 | +$0.00 |
| Jun 2025 | $-0.47 | $-0.54 | $-0.07 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $456K | $52K | — | $1.7M | $2.3M |
| Net Income | — | -$31.8M | -$34.5M | -$41.4M | -$43.8M | -$41.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -19.4% | -19.4% | -19.4% | -19.4% | -19.4% | -21.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -15945.2% | -15945.2% | -15945.2% | -15945.2% | -5062.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.44 |
| Current Ratio | 22.15 | 22.15 | 22.15 | 22.15 | 22.15 | 22.79 |
Key Ratios
ROA (TTM)
-20.8%
P/S (TTM)
1540.60
P/B
2.9
EPS (TTM)
$-2.03
Rev Growth 3Y
-52.1%
52W High
$46.01
52W Low
$14.80
$14.80
52-Week Range
$46.01
Financial Health
Free Cash Flow
-$36.2M
Net Debt
-$25.5M
Cash
$32.5M
Total Debt
$7.0M
As of Dec 31, 2025
How does CGON compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CGON valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1540.6
▲
11889%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
2.9
▲
19%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CGON profitability vs Biotechnology peers
ROE
-21.7%
▲
68%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-5062.5%
▼
1665%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-20.8%
▲
55%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CGON financial health vs Biotechnology peers
D/E ratio
0.4
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
22.8
▲
413%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
2.0
▲
103%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CGON fundamentals radar
CGON
Peer median
Industry
CGON profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CGON vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
MULAY JAMES J. PH.D.
Director · Mar 16
1964 shs
MULAY JAMES J. PH.D.
Director · Mar 16
1964 shs
KUAN ARTHUR
Chief Executive Officer · Mar 12
64612 shs
KUAN ARTHUR
Chief Executive Officer · Mar 04
102871 shs
MULAY JAMES J. PH.D.
Director · Jan 09
11145 shs
MULAY JAMES J. PH.D.
Director · Jan 09
11145 shs
Last 90 days
Top Holders
Top 5: 33.23%Vanguard Group Inc
7.74%
$422.6M
Decheng Capital LLC
7.55%
$411.7M
Wellington Management Group…
7.11%
$387.7M
Blackrock Inc.
5.74%
$313.0M
FMR, LLC
5.09%
$277.7M
As of Dec 31, 2025
Latest News
No related news yet